Skip to main content
Monday, November 16, 2026Nov 16

Merck sues federal government, calling plan to negotiate Medicare drug prices extortion

A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. Merck is suing the federal government Tuesday, June 6, 2023, over a plan to negotiate Medicare drug prices, calling the program a sham equivalent to extortion. The drugmaker is seeking to halt the program, which was laid out in the Inflation Reduction Act and is expected to save taxpayers billions of dollars in the coming years. (AP Photo/Matt Rourke, File)
A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. Merck is suing the federal government Tuesday, June 6, 2023, over a plan to negotiate Medicare drug prices, calling the program a sham equivalent to extortion. The drugmaker is seeking to halt the program, which was laid out in the Inflation Reduction Act and is expected to save taxpayers billions of dollars in the coming years. (AP Photo/Matt Rourke, File)

Merck is suing the federal government over a plan to negotiate Medicare drug prices, calling the program a sham equivalent to extortion.

The drugmaker is seeking to halt the program, which was laid out in the Inflation Reduction Act and is expected to save taxpayers billions of dollars in the coming years.

Merck said in a complaint filed Tuesday that the program does not involve genuine negotiation. Instead, it said the U.S. Department of Health and Human Services selects drugs to be included and then dictates the price, threatening drugmakers with “a ruinous daily excise tax” if they decline to agree.

“It is tantamount to extortion,” the drugmaker said in the complaint, which was filed in the U.S. District Court for the District of Columbia.

The Rahway, New Jersey-based drugmaker added that it expects its diabetes treatment Januvia to be part of “the IRA’s scheme” starting later this year.